BottomBuster Alert DD Post on APNS.OB (.06) Extremely Undervalued Biotech Play w/Major Partners (Eli Lilly, Takeda, & others) & Strong Financial Backing! Major Alzheimer's Conference this week to set opportunities in motion.
http://www.alz.org/icad/
Dinner Presentation by Lilly to discuss the clinical biomarker of APNS.OB
http://www.appliedneurosolutions.com/doc/APNS_8K_April_2008-Lilly-Milestone.doc
Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting
1:00p ET July 14, 2008 (Business Wire)
Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will sponsor a satellite symposium, "Innovative Approaches to Alzheimer's Disease: Developing the Next Generation of Treatment," on Tuesday, July 29.
"With the expected huge increase in the incidence of Alzheimer's disease worldwide in the next 25 years, Pfizer's neuroscience team has made this devastating illness our highest priority," said Dr. Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. "With new insights into the underlying causes of Alzheimer's discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis."
Pfizer's investigational compounds target multiple pathways to combat AD, beta amyloid, the harmful protein that builds up in the brains of AD patients; amyloid plaques, the sticky deposits made of beta amyloid fragments that impair the function of brain cells; chronic inflammation of neurons, and loss of function across the synapses (or gaps) between neurons.
Data from Pfizer to be presented at the meeting include:
-- Receptor for Advanced Glycation End-products (RAGE) Antagonist: Pfizer is in collaboration with TransTech Pharma to develop and commercialize a portfolio of RAGE modulators. RAGE is a cell-surface receptor that may play a key role in multiple aspects of AD. Targeting RAGE for Alzheimer's is a novel approach and Pfizer is pioneering this approach in the clinic. -- Initial Phase II data on the safety and tolerability of Pfizer's oral RAGE antagonist known as PF-04494700 will be presented by Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, AZ, on Wednesday, July 30th at 12:30 p.m. CST. -- Preclinical data on the effect of PF-04494700 on chronic inflammation and buildup of amyloid plaques - two abnormal processes that are implicated in causing damage and death to brain cells in AD - will also be presented by Dr. Jeffrey Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m. CST. -- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the effect of PF-04360365, Pfizer's investigational monoclonal antibody in Phase 1 trials, on beta amyloid levels in the brains of mice will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer, on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are designed to selectively target a specific protein, which, in the case of AD, is beta amyloid.
Additional Preclinical Research:Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain's immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain.
About Alzheimer's Disease
Alzheimer's disease is a progressive disorder characterized by the gradual loss of memory and a decline in cognitive ability; changes in behavior, and a loss in ability to carry out daily activities. It places a tremendous burden on patients, those caring for them, and healthcare systems, costing the U.S. Government more than $148 billion annually. Alzheimer's disease remains one of the world's most undiagnosed diseases, with only one-third of the world's approximately 18 million sufferers receiving treatment.
DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about certain investigational compounds, including their potential benefits in treating Alzheimer's disease, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
Tuesday May 13, 9:30 am ET http://biz.yahoo.com/bw/080513/20080513005944.html?.v=1&printer=1
VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS - News)(www.AppliedNeuroSolutions.com), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD.
The Company’s P-Tau 231 test has been extensively researched and has overall sensitivity and specificity of 85% to 95%. This is based on a broad range of testing by US and international academic researchers to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and other relevant neurological diseases, including major depression, as well as age-matched healthy controls. The data generated from over 2,000 CSF samples have been published in 21 peer-reviewed articles in leading neurology and other scientific journals.
In addition, Applied NeuroSolutions, has to date used the P-Tau 231 test to analyze over 1,500 samples for leading global pharmaceutical companies and is now offering this service to additional customers in response to the growing number of clinical trials to develop better solutions for the increasing AD population. Given the substantial investment required to conduct clinical trials, collection of information provided by the P-Tau 231 test can offer a cost- effective tool to optimize companies’ AD drug development programs.
According to Dr. Mony de Leon, Professor of Psychiatry and Director Center for Brain Health at NYU School of Medicine “P-Tau 231 is now a validated biomarker of neurofibrillary-tangles, a hallmark pathology of Alzheimer’s disease. Among all of the potential AD biomarkers, P-Tau 231 has consistently been the most successful in the diagnosis of AD, not only in the differential diagnosis of Alzheimer’s disease in contrast to other dementias, but also in the very important early stages before the clinical manifestation of AD where the opportunity for therapeutic impact is greatest.”
http://www.alz.org/icad/
Dinner Presentation by Lilly to discuss the clinical biomarker of APNS.OB
http://www.appliedneurosolutions.com/doc/APNS_8K_April_2008-Lilly-Milestone.doc
Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting
1:00p ET July 14, 2008 (Business Wire)
Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will sponsor a satellite symposium, "Innovative Approaches to Alzheimer's Disease: Developing the Next Generation of Treatment," on Tuesday, July 29.
"With the expected huge increase in the incidence of Alzheimer's disease worldwide in the next 25 years, Pfizer's neuroscience team has made this devastating illness our highest priority," said Dr. Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. "With new insights into the underlying causes of Alzheimer's discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis."
Pfizer's investigational compounds target multiple pathways to combat AD, beta amyloid, the harmful protein that builds up in the brains of AD patients; amyloid plaques, the sticky deposits made of beta amyloid fragments that impair the function of brain cells; chronic inflammation of neurons, and loss of function across the synapses (or gaps) between neurons.
Data from Pfizer to be presented at the meeting include:
-- Receptor for Advanced Glycation End-products (RAGE) Antagonist: Pfizer is in collaboration with TransTech Pharma to develop and commercialize a portfolio of RAGE modulators. RAGE is a cell-surface receptor that may play a key role in multiple aspects of AD. Targeting RAGE for Alzheimer's is a novel approach and Pfizer is pioneering this approach in the clinic. -- Initial Phase II data on the safety and tolerability of Pfizer's oral RAGE antagonist known as PF-04494700 will be presented by Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, AZ, on Wednesday, July 30th at 12:30 p.m. CST. -- Preclinical data on the effect of PF-04494700 on chronic inflammation and buildup of amyloid plaques - two abnormal processes that are implicated in causing damage and death to brain cells in AD - will also be presented by Dr. Jeffrey Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m. CST. -- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the effect of PF-04360365, Pfizer's investigational monoclonal antibody in Phase 1 trials, on beta amyloid levels in the brains of mice will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer, on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are designed to selectively target a specific protein, which, in the case of AD, is beta amyloid.
Additional Preclinical Research:Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain's immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain.
About Alzheimer's Disease
Alzheimer's disease is a progressive disorder characterized by the gradual loss of memory and a decline in cognitive ability; changes in behavior, and a loss in ability to carry out daily activities. It places a tremendous burden on patients, those caring for them, and healthcare systems, costing the U.S. Government more than $148 billion annually. Alzheimer's disease remains one of the world's most undiagnosed diseases, with only one-third of the world's approximately 18 million sufferers receiving treatment.
DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about certain investigational compounds, including their potential benefits in treating Alzheimer's disease, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
Tuesday May 13, 9:30 am ET http://biz.yahoo.com/bw/080513/20080513005944.html?.v=1&printer=1
VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS - News)(www.AppliedNeuroSolutions.com), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD.
The Company’s P-Tau 231 test has been extensively researched and has overall sensitivity and specificity of 85% to 95%. This is based on a broad range of testing by US and international academic researchers to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and other relevant neurological diseases, including major depression, as well as age-matched healthy controls. The data generated from over 2,000 CSF samples have been published in 21 peer-reviewed articles in leading neurology and other scientific journals.
In addition, Applied NeuroSolutions, has to date used the P-Tau 231 test to analyze over 1,500 samples for leading global pharmaceutical companies and is now offering this service to additional customers in response to the growing number of clinical trials to develop better solutions for the increasing AD population. Given the substantial investment required to conduct clinical trials, collection of information provided by the P-Tau 231 test can offer a cost- effective tool to optimize companies’ AD drug development programs.
According to Dr. Mony de Leon, Professor of Psychiatry and Director Center for Brain Health at NYU School of Medicine “P-Tau 231 is now a validated biomarker of neurofibrillary-tangles, a hallmark pathology of Alzheimer’s disease. Among all of the potential AD biomarkers, P-Tau 231 has consistently been the most successful in the diagnosis of AD, not only in the differential diagnosis of Alzheimer’s disease in contrast to other dementias, but also in the very important early stages before the clinical manifestation of AD where the opportunity for therapeutic impact is greatest.”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
